One hormone, two actions: Anti- And pro-inflammatory effects of glucocorticoids

NeuroImmunoModulation

Volumn 22, Issue , 2014, Pages 20-32

  Cruz Topete, Diana ^a   Cidlowski, John A ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Glucocorticoid receptor; Glucocorticoids; Immunity; Inflammation; Pro inflammatory and anti inflammatory; Stress hormones

Indexed keywords

GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; HORMONE; STEROID RECEPTOR; DEXAMETHASONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSCRIPTION FACTOR AP 1; ANTIINFLAMMATORY AGENT; CRYOPYRIN; INTERFERON REGULATORY FACTOR 3; INTERLEUKIN 1BETA; INTERLEUKIN 6; PURINERGIC P2Y RECEPTOR; RNA POLYMERASE II; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CORTICOSTEROID THERAPY; HOMEOSTASIS; HORMONE ACTION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; INFLAMMATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; STRESS; ADAPTIVE IMMUNITY; CORTICOSTEROID RELEASE; DRUG ACTIVITY; DRUG EFFECT; GENE REPRESSION; GENETIC ASSOCIATION; INNATE IMMUNITY; LONG TERM CARE; PRIORITY JOURNAL; PRO INFLAMMATORY ACTIVITY; PROTEIN PROCESSING; ANIMAL; BRAIN; CHEMICAL STRUCTURE; CHEMICALLY INDUCED; CHEMISTRY; DRUG EFFECTS; METABOLISM; ALTERNATIVE RNA SPLICING; AMINO TERMINAL SEQUENCE; CARBOXY TERMINAL SEQUENCE; CHROMATIN IMMUNOPRECIPITATION; CONSENSUS SEQUENCE; CYTOKINE RELEASE; CYTOPLASM; DNA BINDING; DNA RESPONSIVE ELEMENT; ENHANCER REGION; EXON; GENE EXPRESSION; HINGE REGION; NONHUMAN; PROMOTER REGION; PROTEIN PHOSPHORYLATION; SUMOYLATION; TRANSCRIPTION INITIATION; TRANSCRIPTION INITIATION SITE; TRANSLATION INITIATION; UBIQUITINATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BRAIN; GLUCOCORTICOIDS; HUMANS; INFLAMMATION; MODELS, MOLECULAR;

EID: 84908575796     PISSN: 10217401     EISSN: 14230216     Source Type: Journal    
DOI: 10.1159/000362724     Document Type: Article

References (81)

1. Sapolsky RM, Romero LM, Munck AU: How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr Rev 2000; 21: 55-89.
2. Oakley RH, Cidlowski JA: The biology of the glucocorticoid receptor: new signaling mechanisms in health and disease. J Allergy Clin Immunol 2013; 132: 1033-1044.
3. Kadmiel M, Cidlowski JA: Glucocorticoid receptor signaling in health and disease. Trends Pharmacol Sci 2013; 34: 518-530.
4. Zhou J, Cidlowski JA: The human glucocorticoid receptor: one gene, multiple proteins and diverse responses. Steroids 2005; 70: 407-417.
5. Vandevyver S, Dejager L, Tuckermann J, Libert C: New insights into the anti-inflammatory mechanisms of glucocorticoids: An emerging role for glucocorticoid-receptormediated transactivation. Endocrinology 2013; 154: 993-1007.
6. Clark AR, Belvisi MG: Maps and legends: The quest for dissociated ligands of the glucocorticoid receptor. Pharmacol Ther 2012; 134: 54-67.
7. Rhen T, Cidlowski JA: Antiinflammatory action of glucocorticoids - new mechanisms for old drugs. N Engl J Med 2005; 353: 1711-1723.
8. Nussinovitch U, de Carvalho JF, Pereira RM, Shoenfeld Y: Glucocorticoids and the cardiovascular system: state of the art. Curr Pharm Des 2010; 16: 3574-3585.
9. Miner JN, Hong MH, Negro-Vilar A: New and improved glucocorticoid receptor ligands. Expert Opin Investig Drugs 2005; 14: 1527-1545.
10. Vanderbilt JN, Miesfeld R, Maler BA, Yamamoto KR: Intracellular receptor concentration limits glucocorticoid-dependent enhancer activity. Mol Endocrinol 1987; 1: 68-74.
11. Danielsen M, Stallcup MR: Down-regulation of glucocorticoid receptors in mouse lymphoma cell variants. Mol Cell Biol 1984; 4: 449- 453.
12. Silva CM, Lu H, Weber MJ, Thorner MO: Differential tyrosine phosphorylation of JAK1, JAK2, and STAT1 by growth hormone and interferon-gamma in IM-9 cells. J Biol Chem 1994; 269: 27532-27539.
13. Barnes PJ, Adcock IM: Glucocorticoid resistance in inflammatory diseases. Lancet 2009; 373: 1905-1917.
14. Busillo JM, Cidlowski JA: The five Rs of glucocorticoid action during inflammation: ready, reinforce, repress, resolve, and restore. Trends Endocrinol Metab 2013; 24: 109-119.
15. Whitfield GK, Jurutka PW, Haussler CA, Haussler MR: Steroid hormone receptors: evolution, ligands, and molecular basis of biologic function. J Cell Biochem 1999;suppl 32- 33: 110-122.
16. Hollenberg SM, Weinberger C, Ong ES, Cerelli G, Oro A, Lebo R, Thompson EB, Rosenfeld MG, Evans RM: Primary structure and expression of a functional human glucocorticoid receptor cDNA. Nature 1985; 318: 635- 641.
17. Nicolaides NC, Galata Z, Kino T, Chrousos GP, Charmandari E: The human glucocorticoid receptor: molecular basis of biologic function. Steroids 2010; 75: 1-12.
18. Beck IM, De Bosscher K, Haegeman G: Glucocorticoid receptor mutants: man-made tools for functional research. Trends Endocrinol Metab 2011; 22: 295-310.
19. Beato M: Gene regulation by steroid hormones. Cell 1989; 56: 335-344.
20. Freedman LP: Anatomy of the steroid receptor zinc finger region. Endocr Rev 1992; 13: 129-145.
21. Uhlenhaut NH, Barish GD, Yu RT, Downes M, Karunasiri M, Liddle C, Schwalie P, Hubner N, Evans RM: Insights into negative regulation by the glucocorticoid receptor from genome-wide profiling of inflammatory cistromes. Mol Cell 2013; 49: 158-171.
22. De Bosscher K, Vanden Berghe W, Haegeman G: Mechanisms of anti-inflammatory action and of immunosuppression by glucocorticoids: negative interference of activated glucocorticoid receptor with transcription factors. J Neuroimmunol 2000; 109: 16-22.
23. De Bosscher K, Vanden Berghe W, Vermeulen L, Plaisance S, Boone E, Haegeman G: Glucocorticoids repress NF-κB-driven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective of coactivator levels in the cell. Proc Natl Acad Sci USA 2000; 97: 3919-3924.
24. So AY, Chaivorapol C, Bolton EC, Li H, Yamamoto KR: Determinants of cell and genespecific transcriptional regulation by the glucocorticoid receptor. PLoS Genet 2007; 3:e94.
25. Surjit M, Ganti KP, Mukherji A, Ye T, Hua G, Metzger D, Li M, Chambon P: Widespread negative response elements mediate direct repression by agonist-liganded glucocorticoid receptor. Cell 2011; 145: 224-241.
26. Ayroldi E, Cannarile L, Migliorati G, Nocentini G, Delfino DV, Riccardi C: Mechanisms of the anti-inflammatory effects of glucocorticoids: genomic and nongenomic interference with MAPK signaling pathways. Faseb J 2012; 26: 4805-4820.
27. Lee SR, Kim HK, Youm JB, Dizon LA, Song IS, Jeong SH, Seo DY, Ko KS, Rhee BD, Kim N, et al: Non-genomic effect of glucocorticoids on cardiovascular system. Pflugers Arch 2012; 464: 549-559.
28. Yudt MR, Cidlowski JA: Molecular identification and characterization of A and B forms of the glucocorticoid receptor. Mol Endocrinol 2001; 15: 1093-1103.
29. Gross KL, Cidlowski JA: Tissue-specific glucocorticoid action: A family affair. Trends Endocrinol Metab 2008; 19: 331-339.
30. Oakley RH, Sar M, Cidlowski JA: The human glucocorticoid receptor β isoform. Expression, biochemical properties, and putative function. J Biol Chem 1996; 271: 9550-9559.
31. Oakley RH, Cidlowski JA: Cellular processing of the glucocorticoid receptor gene and protein: new mechanisms for generating tissuespecific actions of glucocorticoids. J Biol Chem 2011; 286: 3177-3184.
32. Bamberger CM, Bamberger AM, de Castro M, Chrousos GP: Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans. J Clin Invest 1995; 95: 2435-2441.
33. Kino T, Su YA, Chrousos GP: Human glucocorticoid receptor isoform beta: recent understanding of its potential implications in physiology and pathophysiology. Cell Mol Life Sci 2009; 66: 3435-3448.
34. Lewis-Tuffin LJ, Cidlowski JA: The physiology of human glucocorticoid receptor beta (hGRβ) and glucocorticoid resistance. Ann NY Acad Sci 2006; 1069: 1-9.
35. Kino T, Manoli I, Kelkar S, Wang Y, Su YA, Chrousos GP: Glucocorticoid receptor (GR) β has intrinsic, GRα-independent transcriptional activity. Biochem Biophys Res Commun 2009; 381: 671-675.
36. Avenant C, Ronacher K, Stubsrud E, Louw A, Hapgood JP: Role of ligand-dependent GR phosphorylation and half-life in determination of ligand-specific transcriptional activity. Mol Cell Endocrinol 2010; 327: 72-88.
37. Wang Z, Frederick J, Garabedian MJ: Deciphering the phosphorylation 'code' of the glucocorticoid receptor in vivo. J Biol Chem 2002; 277: 26573-26580.
38. Webster JC, Jewell CM, Bodwell JE, Munck A, Sar M, Cidlowski JA: Mouse glucocorticoid receptor phosphorylation status influences multiple functions of the receptor protein. J Biol Chem 1997; 272: 9287-9293.
39. Miller AL, Webb MS, Copik AJ, Wang Y, Johnson BH, Kumar R, Thompson EB: p38 mitogen-activated protein kinase (MAPK) is a key mediator in glucocorticoid-induced apoptosis of lymphoid cells: correlation between p38 MAPK activation and site-specific phosphorylation of the human glucocorticoid receptor at serine 211. Mol Endocrinol 2005; 19: 1569-1583.
40. Chen W, Dang T, Blind RD, Wang Z, Cavasotto CN, Hittelman AB, Rogatsky I, Logan SK, Garabedian MJ: Glucocorticoid receptor phosphorylation differentially affects target gene expression. Mol Endocrinol 2008; 22: 1754-1766.
41. Galliher-Beckley AJ, Williams JG, Collins JB, Cidlowski JA: Glycogen synthase kinase 3β-mediated serine phosphorylation of the human glucocorticoid receptor redirects gene expression profiles. Mol Cell Biol 2008; 28: 73097322.
42. Galliher-Beckley AJ, Williams JG, Cidlowski JA: Ligand-independent phosphorylation of the glucocorticoid receptor integrates cellular stress pathways with nuclear receptor signaling. Mol Cell Biol 2011; 31: 4663-4675.
43. Wallace AD, Cidlowski JA: Proteasome-mediated glucocorticoid receptor degradation restricts transcriptional signaling by glucocorticoids. J Biol Chem 2001; 276: 42714- 42721.
44. Druker J, Liberman AC, Antunica-Noguerol M, Gerez J, Paez-Pereda M, Rein T, Iniguez- Lluhi JA, Holsboer F, Arzt E: RSUME enhances glucocorticoid receptor SUMOylation and transcriptional activity. Mol Cell Biol 2013; 33: 2116-2127.
45. Ito K, Yamamura S, Essilfie-Quaye S, Cosio B, Ito M, Barnes PJ, Adcock IM: Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-κB suppression. J Exp Med 2006; 203: 7-13.
46. Charmandari E, Chrousos GP, Lambrou GI, Pavlaki A, Koide H, Ng SS, Kino T: Peripheral CLOCK regulates target-tissue glucocorticoid receptor transcriptional activity in a circadian fashion in man. PLoS One 2011; 6:e25612.
47. Sorrells SF, Sapolsky RM: An inflammatory review of glucocorticoid actions in the CNS. Brain Behav Immun 2007; 21: 259-272.
48. Dhabhar FS: Stress-induced augmentation of immune function - The role of stress hormones, leukocyte trafficking, and cytokines. Brain Behav Immun 2002; 16: 785-798.
49. Dhabhar FS, McEwen BS: Enhancing versus suppressive effects of stress hormones on skin immune function. Proc Natl Acad Sci USA 1999; 96: 1059-1064.
50. Deinzer R, Granrath N, Stuhl H, Twork L, Idel H, Waschul B, Herforth A: Acute stress effects on local Il-1β responses to pathogens in a human in vivo model. Brain Behav Immun 2004; 18: 458-467.
51. O'Connor KA, Johnson JD, Hansen MK, Wieseler Frank JL, Maksimova E, Watkins LR, Maier SF: Peripheral and central proinflammatory cytokine response to a severe acute stressor. Brain Res 2003; 991: 123-132.
52. Bowers SL, Bilbo SD, Dhabhar FS, Nelson RJ: Stressor-specific alterations in corticosterone and immune responses in mice. Brain Behav Immun 2008; 22: 105-113.
53. Akira S, Uematsu S, Takeuchi O: Pathogen recognition and innate immunity. Cell 2006; 124: 783-801.
54. Pancer Z, Cooper MD: The evolution of adaptive immunity. Annu Rev Immunol 2006; 24: 497-518.
55. Bhattacharyya S, Brown DE, Brewer JA, Vogt SK, Muglia LJ: Macrophage glucocorticoid receptors regulate Toll-like receptor 4-mediated inflammatory responses by selective inhibition of p38 MAP kinase. Blood 2007; 109: 4313-4319.
56. Tuckermann JP, Kleiman A, Moriggl R, Spanbroek R, Neumann A, Illing A, Clausen BE, Stride B, Forster I, Habenicht AJ, et al: Macrophages and neutrophils are the targets for immune suppression by glucocorticoids in contact allergy. J Clin Invest 2007; 117: 1381- 1390.
57. Barnes PJ: How corticosteroids control inflammation: Quintiles Prize Lecture 2005. Br J Pharmacol 2006; 148: 245-254.
58. Hess J, Angel P, Schorpp-Kistner M: AP-1 subunits: quarrel and harmony among siblings. J Cell Sci 2004; 117(pt 25):5965-5973.
59. Johnson GL, Lapadat R: Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002; 298: 1911-1912.
60. Kumar A, Takada Y, Boriek AM, Aggarwal BB: Nuclear factor-κB: its role in health and disease. J Mol Med (Berl) 2004; 82: 434-448.
61. Liden J, Delaunay F, Rafter I, Gustafsson J, Okret S: A new function for the C-terminal zinc finger of the glucocorticoid receptor: repression of RelA transactivation. J Biol Chem 1997; 272: 21467-21472.
62. Reily MM, Pantoja C, Hu X, Chinenov Y, Rogatsky I: The GRIP1:IRF3 interaction as a target for glucocorticoid receptor-mediated immunosuppression. Embo J 2006; 25: 108-117.
63. McKay LI, Cidlowski JA: CBP (CREB binding protein) integrates NF-κB (nuclear factor-κB) and glucocorticoid receptor physical interactions and antagonism. Mol Endocrinol 2000; 14: 1222-1234.
64. Nissen RM, Yamamoto KR: The glucocorticoid receptor inhibits NFκB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain. Genes Dev 2000; 14: 2314-2329.
65. Murphy SH, Suzuki K, Downes M, Welch GL, De Jesus P, Miraglia LJ, Orth AP, Chanda SK, Evans RM, Verma IM: Tumor suppressor protein (p)53, is a regulator of NF-κB repression by the glucocorticoid receptor. Proc Natl AcadSci USA 2011; 108: 17117-17122.
66. Smoak K, Cidlowski JA: Glucocorticoids regulate tristetraprolin synthesis and posttranscriptionally regulate tumor necrosis factor alpha inflammatory signaling. Mol Cell Biol 2006; 26: 9126-9135.
67. Carrick DM, Lai WS, Blackshear PJ: The tandem CCCH zinc finger protein tristetraprolin and its relevance to cytokine mRNA turnover and arthritis. Arthritis Res Ther 2004; 6: 248- 264.
68. Dhabhar FS: A hassle a day may keep the doctor away: stress and the augmentation of immune function. Integr Comp Biol 2002; 42: 556-564.
69. Chinenov Y, Rogatsky I: Glucocorticoids and the innate immune system: crosstalk with the toll-like receptor signaling network. Mol Cell Endocrinol 2007; 275: 30-42.
70. Galon J, Franchimont D, Hiroi N, Frey G, Boettner A, Ehrhart-Bornstein M, O'Shea JJ, Chrousos GP, Bornstein SR: Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. Faseb J 2002; 16: 61-71.
71. Homma T, Kato A, Hashimoto N, Batchelor J, Yoshikawa M, Imai S, Wakiguchi H, Saito H, Matsumoto K: Corticosteroid and cytokines synergistically enhance toll-like receptor 2 expression in respiratory epithelial cells. Am J Respir Cell Mol Biol 2004; 31: 463-469.
72. Hermoso MA, Matsuguchi T, Smoak K, Cidlowski JA: Glucocorticoids and tumor necrosis factor alpha cooperatively regulate Tolllike receptor 2 gene expression. Mol Cell Biol 2004; 24: 4743-4756.
73. Shuto T, Imasato A, Jono H, Sakai A, Xu H, Watanabe T, Rixter DD, Kai H, Andalibi A, Linthicum F, et al: Glucocorticoids synergistically enhance nontypeable Haemophilus influenzae -induced Toll-like receptor 2 expression via a negative cross-talk with p38 MAP kinase. J Biol Chem 2002; 277: 17263-17270.
74. Bornstein SR, Zacharowski P, Schumann RR, Barthel A, Tran N, Papewalis C, Rettori V, McCann SM, Schulze-Osthoff K, Scherbaum WA, et al: Impaired adrenal stress response in Toll-like receptor 2-deficient mice. Proc Natl AcadSci USA 2004; 101: 16695-16700.
75. Lannan EA, Galliher-Beckley AJ, Scoltock AB, Cidlowski JA: Proinflammatory actions of glucocorticoids: glucocorticoids and TNFα coregulate gene expression in vitro and in vivo. Endocrinology 2012; 153: 3701-3712.
76. Langlais D, Couture C, Balsalobre A, Drouin J: Regulatory network analyses reveal genome- wide potentiation of LIF signaling by glucocorticoids and define an innate cell defense response. PLoS Genet 2008; 4:e1000224.
77. Busillo JM, Azzam KM, Cidlowski JA: Glucocorticoids sensitize the innate immune system through regulation of the NLRP3 inflammasome. J Biol Chem 2011; 286: 38703-38713.
78. Ding Y, Gao ZG, Jacobson KA, Suffredini AF: Dexamethasone enhances ATP-induced inflammatory responses in endothelial cells. J Pharmacol Exp Ther 2010; 335: 693-702.
79. Brewer JA, Khor B, Vogt SK, Muglia LM, Fujiwara H, Haegele KE, Sleckman BP, Muglia LJ: T-cell glucocorticoid receptor is required to suppress COX-2-mediated lethal immune activation. Nat Med 2003; 9: 1318-1322.
80. Kim CJ, Woo YJ, Kim GH, Yoo HW: Familial glucocorticoid deficiency with a point mutation in the ACTH receptor: A case report. J Korean Med Sci 2009; 24: 979-981.
81. Duma D, Collins JB, Chou JW, Cidlowski JA: Sexually dimorphic actions of glucocorticoids provide a link to inflammatory diseases with gender differences in prevalence. Sci Signal 2010; 3:ra74.